Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


10.04.2017

1 Acta Radiol
2 AJR Am J Roentgenol
3 Anticancer Res
6 BJU Int
1 BMC Urol
1 Cancer
2 Cancer Lett
1 Clin Cancer Res
1 Endocrinology
1 Eur Radiol
6 Eur Urol
1 Int J Oncol
2 J Clin Oncol
1 J Magn Reson Imaging
3 J Natl Cancer Inst
1 J Nucl Med
2 J Urol
3 Lancet Oncol
3 Nat Rev Urol
2 Oncogene
1 Oncol Rep
4 PLoS One
1 Prog Urol
1 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Radiol

  1. GODLEY KC, Syer TJ, Toms AP, Smith TO, et al
    Accuracy of high b-value diffusion-weighted MRI for prostate cancer detection: a meta-analysis.
    Acta Radiol. 2017 Jan 1:284185117702181. doi: 10.1177/0284185117702181.
    PubMed     Text format     Abstract available


    AJR Am J Roentgenol

  2. KIRSCH AJ, Coakley FV, Foster BR
    A Modified Approach for Transgluteal Prostate Biopsy in Patients Without Rectal Access.
    AJR Am J Roentgenol. 2016;207:W20.
    PubMed     Text format    

  3. ROSENKRANTZ AB, Ayoola A, Hoffman D, Khasgiwala A, et al
    The Learning Curve in Prostate MRI Interpretation: Self-Directed Learning Versus Continual Reader Feedback.
    AJR Am J Roentgenol. 2016 Dec 27:W1-W9. doi: 10.2214/AJR.16.16876.
    PubMed     Text format     Abstract available


    Anticancer Res

  4. JOHANSSON AK, Lennernas B, Isacsson U
    Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer.
    Anticancer Res. 2017;37:1825-1830.
    PubMed     Text format     Abstract available

  5. MABUCHI M, Ueda M, Yoshida Y, Horiike K, et al
    Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
    Anticancer Res. 2017;37:1665-1676.
    PubMed     Text format     Abstract available

  6. PARK J, Joung JY, Hwang JE, Hong D, et al
    Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility.
    Anticancer Res. 2017;37:1687-1696.
    PubMed     Text format     Abstract available


    BJU Int

  7. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Text format     Abstract available

  8. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Text format     Abstract available

  9. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Text format     Abstract available

  10. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Text format     Abstract available

  11. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Text format     Abstract available

  12. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Text format     Abstract available


    BMC Urol

  13. POSTEMA AW, Scheltema MJ, Mannaerts CK, Van Sloun RJ, et al
    The prostate cancer detection rates of CEUS-targeted versus MRI-targeted versus systematic TRUS-guided biopsies in biopsy-naive men: a prospective, comparative clinical trial using the same patients.
    BMC Urol. 2017;17:27.
    PubMed     Text format     Abstract available


    Cancer

  14. LAYNE TM, Weinstein SJ, Graubard BI, Ma X, et al
    Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30634.
    PubMed     Text format     Abstract available


    Cancer Lett

  15. TAKAYAMA K, Inoue T, Narita S, Maita S, et al
    Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30216.
    PubMed     Text format     Abstract available

  16. LIN SJ, Chou FJ, Li L, Lin CY, et al
    Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30217.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  17. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Text format     Abstract available


    Endocrinology

  18. HO Y, Dehm SM
    Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Endocrinology. 2017 Mar 27. doi: 10.1210/en.2017-00109.
    PubMed     Text format     Abstract available


    Eur Radiol

  19. WANG J, Wu CJ, Bao ML, Zhang J, et al
    Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
    Eur Radiol. 2017 Apr 3. doi: 10.1007/s00330-017-4800.
    PubMed     Text format     Abstract available


    Eur Urol


  20. Prostate Cancer and the John West Effect.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30095.
    PubMed     Text format     Abstract available

  21. SCHWEIZER MT, Antonarakis ES, Denmeade SR
    Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30233.
    PubMed     Text format     Abstract available

  22. KIM JH, Khandwala YS, Chung BI
    Re: Jim C. Hu, David M. Nanus, Art Sedrakyan. Increase in prostate cancer metastases at radical prostatectomy in the United States. Eur Urol 2017;71:147-9.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30234.
    PubMed     Text format    

  23. SCHROECK FR, Jacobs BL, Bhayani SB, Nguyen PL, et al
    Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Eur Urol. 2017 Mar 30. pii: S0302-2838(17)30239.
    PubMed     Text format     Abstract available

  24. DUTTA A, Panja S, Virk RK, Kim JY, et al
    Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5alpha-reductase Inhibition.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30252.
    PubMed     Text format     Abstract available

  25. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231.
    PubMed     Text format     Abstract available


    Int J Oncol

  26. HARTING T, Stubbendorff M, Willenbrock S, Wagner S, et al
    The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro.
    Int J Oncol. 2016;49:2341-2350.
    PubMed     Text format     Abstract available


    J Clin Oncol

  27. ANTONARAKIS ES, Lu C, Luber B, Wang H, et al
    Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 6:JCO2016701961. doi: 10.1200/JCO.2016.70.1961.
    PubMed     Text format     Abstract available

  28. SMITH BYRNE K, Castano JM, Chirlaque MD, Lilja H, et al
    Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
    J Clin Oncol. 2017 Mar 6:JCO2016700062. doi: 10.1200/JCO.2016.70.0062.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  29. KRISHNA S, Lim CS, McInnes MD, Flood TA, et al
    Evaluation of MRI for diagnosis of extraprostatic extension in prostate cancer.
    J Magn Reson Imaging. 2017 Apr 7. doi: 10.1002/jmri.25729.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  30. BRIOLLAIS L, Ozcelik H, Xu J, Kwiatkowski M, et al
    Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available

  31. KELLY SP, Graubard BI, Andreotti G, Younes N, et al
    Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2017;109:1-9.
    PubMed     Text format     Abstract available

  32. POLLACK A, Kwon D, Walker G, Khor LY, et al
    Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
    J Natl Cancer Inst. 2017;109:1-8.
    PubMed     Text format     Abstract available


    J Nucl Med

  33. MILLER MP, Kostakoglu L, Pryma D, Yu JQ, et al
    Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
    J Nucl Med. 2017 Apr 6. pii: jnumed.116.188375. doi: 10.2967/jnumed.116.188375.
    PubMed     Text format     Abstract available


    J Urol

  34. DISTLER FA, Radtke JP, Bonekamp D, Kesch C, et al
    The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43846-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  35. MEHRALIVAND S, Bednarova S, Shih JH, Mertan FV, et al
    Prospective Evaluation of Prostate Imaging-Reporting and Data System Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43847-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Lancet Oncol

  36. AZZOUZI AR, Emberton M
    Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply.
    Lancet Oncol. 2017;18:e188.
    PubMed     Text format    

  37. VENKATESAN P
    Quality of life after treatments for prostate cancer.
    Lancet Oncol. 2017 Mar 30. pii: S1470-2045(17)30244.
    PubMed     Text format    

  38. YAN W, Zhou Y, Zhou Z, Ji Z, et al
    Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer.
    Lancet Oncol. 2017;18:e187.
    PubMed     Text format    


    Nat Rev Urol

  39. STONE L
    Prostate cancer: In a SNP: KLK6 mutations in aggressive disease.
    Nat Rev Urol. 2017 Apr 4. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  40. STONE L
    Prostate cancer: Feel it in your bones: MAOA mediates metastasis.
    Nat Rev Urol. 2017 Apr 4. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  41. SIDAWAY P
    Prostate cancer: Enzalutamide promotes mesenchymal plasticity via Snail activation.
    Nat Rev Urol. 2017 Apr 4. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncogene

  42. DI GIACOMO V, Tian TV, Mas A, Pecoraro M, et al
    DeltaNp63alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available

  43. KO CJ, Lan SW, Lu YC, Cheng TS, et al
    Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  44. KONG Q, Chen XS, Tian T, Xia XY, et al
    MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
    Oncol Rep. 2017;37:803-812.
    PubMed     Text format     Abstract available


    PLoS One

  45. FAN CY, Huang WY, Lin CS, Su YF, et al
    Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.
    PLoS One. 2017;12:e0175217.
    PubMed     Text format     Abstract available


  46. Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLoS One. 2017;12:e0175606.
    PubMed     Text format     Abstract available

  47. PANG KH, Rosario DJ, Morgan SL, Catto JW, et al
    Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.
    PLoS One. 2017;12:e0175070.
    PubMed     Text format     Abstract available

  48. ROHENA-RIVERA K, Sanchez-Vazquez MM, Aponte-Colon DA, Forestier-Roman IS, et al
    IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.
    PLoS One. 2017;12:e0172786.
    PubMed     Text format     Abstract available


    Prog Urol

  49. BARRE C, Nguyen JM
    [Addendum concerning: "A prospective trial comparing consecutive series of open retropubic and robot-assisted laparoscopic radical prostatectomy in a centre: Oncologic and functional outcomes" written by J.B. Beauval et al. [Prog. Urol. 25 (2015) 370-
    Prog Urol. 2016;26:383-4.
    PubMed     Text format    


    Prostate

  50. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
    External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
    Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: